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Abstract: Schizophrenia and Bipolar Disorder are chronic psychiatric disorders, both considered as 
“major psychosis”; they are thought to share some pathogenetic factors involving a dysfunctional 
gene x environment interaction. Alterations in the glutamatergic transmission have been suggested to 
be involved in the pathogenesis of psychosis. Our group developed an epigenetic model of 
schizophrenia originated by Prenatal Restraint Stress (PRS) paradigm in mice. PRS mice developed some behavioral 
alterations observed in schizophrenic patients and classic animal models of schizophrenia, i.e. deficits in social 
interaction, locomotor activity and prepulse inhibition. They also showed specific changes in promoter DNA methylation 
activity of genes related to schizophrenia such as reelin, BDNF and GAD67, and altered expression and function of 
mGlu2/3 receptors in the frontal cortex. Interestingly, behavioral and molecular alterations were reversed by treatment 
with mGlu2/3 agonists. Based on these findings, we speculate that pharmacological modulation of these receptors could 
have a great impact on early phase treatment of psychosis together with the possibility to modulate specific epigenetic key 
protein involved in the development of psychosis. 
In this review, we will discuss in more details the specific features of the PRS mice as a suitable epigenetic model for 
major psychosis. We will then focus on key proteins of chromatin remodeling machinery as potential target for new 
pharmacological treatment through the activation of metabotropic glutamate receptors. 
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INTRODUCTION 
 Schizophrenia and Bipolar Disorder are severe and 
chronic psychiatric disorders, both considered as “major 
psychosis” that are thought to share several pathogenetic 
factors involving a dysfunctional “gene x environment” 
interaction. Epigenetic events in telencephalic GABAergic 
and glutamatergic neurons contribute to the pathogenesis  
of psychotic symptoms in patients affected by schizophrenia 
[1, 2]. Atypical antipsychotics and valproic acid, drugs 
commonly used to treat psychosis, have been demonstrated 
to exert a potential effect on epigenetic mechanisms and to 
modulate chromatin structure remodeling by inducing DNA 
demethylation and histone modifications [3, 4]. The term 
“epigenetic” refers to stable alterations in chromatin 
structure and genes expression that occur without modifying 
the underlying DNA sequence [5]. These alterations strongly 
depend on gene-environment interactions, can be transmitted 
through generations of cell divisions and may induce 
phenotypic modifications in the organisms [6]. Epigenetic 
modifications of the genome may occur via different  
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pathways: (i) cytosine DNA methylation at specific clusters 
of dinucleotyde sequence (CpG) by a family of enzymes 
called DNA methyltransferases (DNMTs); (ii) covalent 
modifications of histones at their amino (N)-terminal tails, 
the most important of which being acetylation and 
methylation; (iii) RNA interference [7-10] (Fig. 1). In recent 
years, an increasing interest arose among the scientific 
community on this topic: epigenetic mechanisms have been 
identified in the pathogenesis of many diseases, including 
psychiatric diseases [11-16], and the development of drugs 
with specific ability to modulate the epigenetic machinery is 
at the moment a very intriguing and promising therapeutic 
strategy. 
MODELING THE MOLECULAR EPIGENETIC 
PROFILE OF PSYCHOSIS IN PRENATALLY 
STRESSED MICE 
 Evidence from neuroimaging, neuropathology, and 
epidemiological studies has led to the conclusion that 
schizophrenia (SZ) and bipolar (BP) disorders are likely to 
be neurodevelopmental disorders that originate before birth 
[17-19]. Moreover, an association between prenatal stress 
and risk for developing SZ and associated psychiatric 
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 Adult offspring of mice exposed to repeated episodes of 
restraint stress during pregnancy, here defined as prenatally 
restraint stressed mice or PRS mice, exhibit a SZ-like 
behavioral phenotype characterized by hyperactivity, 
stereotyped and compulsive behaviors, deficits in social 
interaction, pre-pulse inhibition (PPI), fear conditioning,  
and object recognition, and hypersensitivity to N-methyl  
D-aspartate (NMDA) receptor blockers. This behavioral 
phenotype recapitulates positive and negative symptoms, as 
well as cognitive dysfunction displayed by patients affected 
by SZ or BP disorder [23]. PRS mice also show a deficit in 
cortical GABAergic innervation [23-25], which is expected 
to cause abnormal synchronization of the firing rate of 
pyramidal neurons, a putative electrophysiological substrate 
of cognitive dysfunction in psychotic patients [1, 26, 27] and 
neurodevelopmental animal models of SZ [28]. 
 From a molecular standpoint, PRS mice show a disrupted 
signature of chromatin remodeling at genes typically 
expressed in GABAergic and glutamatergic neurons, i.e., 
genes encoding for glutamate decarboxylase-67 (GAD1), 
reelin (RELN) and brain derived neurotrophic factor (BDNF) 
respectively [23, 29, 30]. These molecular changes in PRS 
mice are similar to those observed in the brain of SZ and  
BP patients, [2, 31-35] strongly suggesting that aberrant 
epigenetic GABAergic/glutamatergic mechanisms may 
underlie psychotic symptoms. 
 The epigenetic endophenotypes common to the Frontal 
Cortex (FC) and hippocampus of PRS mice and the brain of 
patients affected by SZ and BP disorder are the following: (i) 
increased mRNA and protein levels of the DNA methylating 
enzymes, DNA methyltransferase 1 (DNMT1) and ten-
eleven metylcytosine dioxygenase -1 (TET1); (ii) enhanced 
DNMT1 binding to GAD1, RELN, and BDNF-IX promoters; 
(iii) increased levels of 5-methylcytosine (5MC) and  
 
Fig. (1). A schematic organizations of chromatin structure (a). DNA is classically wrapped around histone proteins forming the basic units 
known as nucleosomes. These complexes consist in two copies of H2A, H2B, H3, and H4 proteins. H2B, H3, and H4 have their N-terminal 
tails protruding from the nucleosome. H2A has also the C-terminal protruding from the nucleosome. The tails undergo to posttranslational 
modifications such as acethylation and methylation as shown in (b) in addition to DNA epigenetic modifications such as methylation at CpG 
islands and demethylation (not shown). This image was originally published in Sun HS, Kennedy PJ, Nestler EJ. Epigenetics of the 
depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology Rev., 2013, 38, 124137. The author retains the 
copyright. 
 
Fig. (2). A schematic enzyme-based reaction cascade of DNA 
methylation and de-methylation at cytosine residues involving 
DNA methylatransferase (DNMT), Ten-eleven translocation (TET) 
enzymes, which hydroxylate 5-methyl cytosine (5MC) to form  
5-hydroxymethylcytosine (5HMC), and cytidine deaminases 
(Apobec), that, through a growth arrest and DNA damage 
(GADD45) protein-coordinated process (not shown), convert 
5HMC to 5-hydroxymethyuracil (5HMU), which can be excised by 
thymine glycosylases, leading to the non-methylated state. Base 
Excision Repair [BER] enzymes remove methyl groups from 
cytosines. This image was originally published in Guidotti A,  
Dong E, Tueting P, Grayson DR. Modeling the molecular 
epigenetic profile of psychosis in prenatally stressed mice. Prog. 
Mol. Biol. Trans. Sci., 2014, 128, 89-101. The author retains the 
copyright. 
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5-hydroxymethylcytosine (5HMC) at GAD1, RELN, and 
BDNF promoters; (iv) increased binding of methyl CpG 
binding protein (MeCP2) to GAD1 and RELN promoters; 
and (v) a reduced expression of GAD1, RELN and several 
BDNF-splice variants [2, 23, 30, 31, 36-38] (Fig. 2). 
 Different studies [23, 39, 40] have shown that the SZ-like 
behavioral alterations present in neurodevelopmental rodent 
models of SZ are corrected by systemic administration of 
valproate and clozapine. In the present review, we address 
the question of whether PRS mice may provide a behavioural 
and molecular epigenetic animal model of SZ valuable for 
the study of the antipsychotic-like activity of types-2/3 
metabotropic glutamate (mGlu2/3) receptor agonists and 
their interaction with typical or atypical antipsychotic drugs. 
METABOTROPIC GLUTAMATE 2/3 RECEPTOR 
AGONISTS AND SCHIZOPHRENIA 
 Metabotropic glutamate receptors are GTP-binding-
protein (G-protein) coupled receptors that modulate both 
excitatory and inhibitory synaptic transmission in the CNS, 
and are considered as candidate drug targets for neurological 
and psychiatric disorders [41]. 
 In the last decade, a role for mGlu2/3 receptors in 
schizophrenia has been suggested by preclinical and clinical 
studies. Pharmacological activation of mGlu2/3 receptors 
decreases glutamate release in the CNS, thereby reducing 
synaptic firing. This effect is shared with atypical 
antipsychotic drugs such as clozapine, which suppress 
serotonin-induced post-synaptic excitation in different brain 
regions [42] (Fig. 3). Both orthosteric mGlu2/3 receptor 
agonists and selective mGlu2 receptor enhancers reverse the 
effect of NMDA receptor antagonists on working memory, 
sensorimotor gating, locomotor activity, and cortical 
glutamate efflux in rodents [43-47]. In addition, drugs that 
activate mGlu2/3 receptors restrain the electrophysiological 
and behavioral effects of agents acting on 5-HT2A serotonin 
receptors, i.e. hallucinogens [48-52]. In patients affected by 
schizophrenia, systemic treatment with pomeglumetad 
methionyl, an oral prodrug of the mGlu2/3 receptor agonist, 
LY404039, displayed significant antipsychotic activity in a 
Phase-2 clinical trial [53], but not in subsequent trials [54, 
55]. Perhaps a reason for these contrasting findings was the 
recruitment of patients that had been treated with atypical 
antipsychotic drugs, which are known to epigenetically 
down-regulate mGlu2 receptors in mice [56, 57]. Thus, 
mGlu2/3 agonists might still be promising for the treatment 
of targeted subpopulations of patients affected by SZ. 
PHARMACOLOGICAL ACTIVATION OF mGlu2/3 
RECEPTORS CORRECTS THE PATHOLOGICAL 
PHENOTYPE OF PRS MICE 
 As outlined above, PRS mice exhibit a SZ-like phenotype 
characterized by alterations in in social interaction, prepulse 
inhibition, and locomotor activity, and, by an epigenetic 
down-regulation of reelin, BDNF, and GAD67 proteins in 
the frontal cortex and hippocampus [23]. 
 Interestingly, PRS mice also showed significant 
reductions in mGlu2 and mGlu3 receptor mRNA and protein 
levels in the frontal cortex, which was manifest at birth and, 
at least for mGlu2 receptors, persisted in adult life. This 
 
Fig. (3). A schematic cartoon showing the interactions between GABAergic and glutamatergic neurotransmission at cortical level. 
Unbalanced GABA/glutamate neurotransmission is proposed as the main pathogenetic mechanism underlying psychosis. Hypofunction of 
GABA interneurons via NMDA receptors leads to disinhibition of cortical glutamatergic pyramidal cells causing an excessive activation and 
glutamate release. The same fibers project to subcortical areas causing an excessive firing and dopamine release. The cartoon shows also 
different types of receptors, such as mGlu2/3 receptors at presynaptic level and 5-HT2a as potential target for pharmacological interventions 
to restore the normal balance between GABA and glutamate. DA = dopaminergic. 
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reduction was associated with an increased binding of 
DNMT1 to CpG-rich regions of the GRM2 and GRM3 gene 
promoters and an increased binding of MeCP2 to the GRM2 
receptor promoter [2]. 
 More recently, we have found a significant increase  
of TET1 (the enzyme that catalyzes the transformation of  
5-methylcytosine (5-mC) into 5-hydroxymethylcytosine  
(5-hmC) in the frontal cortex of PRS mice [30]. 
 All epigenetic and behavioral changes of PRS mice were 
reversed by treatment with the mGlu2/3 receptor agonist, 
LY379268 [29]. A reduced expression of DNMT1 and 
DNMT3a was also observed in response to LY354740 
(another potent mGlu2/3 receptor agonist) (Authors’ 
unpublished observation). 
 In addition LY379268 increased both mRNA and protein 
levels of growth arrest and DNA damage 45-β (Gadd45-β), a 
protein involved in the regulation of DNA demethylation, in 
mice frontal cortex and hippocampus. The binding of 
Gadd45-β to specific promoter regions of RELN, BDNF, and 
GAD1 genes was also increased after treatment with 
LY379268 [58]. 
 The effects of mGlu2/3 receptor agonists in PRS mice 
were similar to those produced by the atypical antipsychotic 
clozapine and by valproate, a drug that has multiple 
mechanisms of action including the inhibition of HDACs 
[59]. In contrast, the classical antipsychotic, haloperidol, had 
no effect on PRS mice. 
 All together, these findings suggest that treatment with 
mGlu2/3 receptor agonists or mGlu2 receptor PAMs might 
correct epigenetic alterations typical of patients affected by 
SZ. 
5HT2A-mGlu2/3 RECEPTOR INTERACTIONS 
 A large body of evidence suggests that 5-HT2A and 
mGlu2 receptors tightly interact in regulating the response of 
cortical pyramidal neurons to thalamic inputs in the 
prefrontal cortex, and that this interaction is relevant to the 
pathophysiology of schizophrenia. Activation of 5-HT2A 
receptors enhances glutamate release in the apical dendritic 
region of cortical layer V pyramidal cells, and this effect is 
blocked by pharmacological activation of presynaptic 
mGlu2/3 receptors [60]. Gonzales-Maeso and his associates 
have shown that mGlu2 physically associates with 5-HT2A 
receptors via specific amino acid residues located at the C-
terminal end of the 4th transmembrane (TM) domain, and 
that activation of mGlu2 receptors restrains specific 
signaling pathways activated by hallucinogens acting at 5-
HT2A receptors [61-63]. The finding that expression of 
mGlu2 receptors is reduced, and expression of 5-HT2A 
receptors is increased, in post-mortem cortical tissue of 
patients affected by SZ [61] suggests that an imbalance 
between mGlu2 and 5-HT2A receptors contributes to the 
pathophysiology of SZ and can be targeted by therapeutic 
intervention. This imbalance was also shown in prenatally 
stressed mice, and in the adult progeny of dams exposed to 
viral infection during pregnancy. In both models, early life 
stress caused a down-regulation of mGlu2 receptors and an 
up-regulation of 5-HT2A receptors in the cerebral cortex in 
the adult life [64, 65]. These changes in receptor expression 
might not be interrelated because it is the blockade or genetic 
deletion of 5-HT2A receptors that epigenetically down-
regulate mGlu2 receptors [56, 57]. 5-HT2A receptor knockout 
mice showed a reduced expression of mGlu2 receptors in the 
frontal cortex, which was associated with a reduced H3 and 
H4 histone acetylation and an increased H3-K27 tri-
methylation at the GRM2 gene promoter, two epigenetic 
changes that cause gene repression [56]. Similar changes 
were found in normal mice chronically treated with atypical 
antipsychotic drugs inhibiting 5-HT2A receptors [56]. 
CONCLUSIONS 
 All these findings suggest that mGlu2 and 5-HT2A 
receptors are specifically targeted by a pathological 
epigenetic programming that is triggered by adverse events 
occurring early in life and that ultimately results in a long-
lasting dysfunction of thalamic-cortical transmission, which is 
a key event in the pathophysiology of SZ. Pharmacological 
activation of mGlu2 receptors seems to have a favorable 
impact on epigenetic changes associated with SZ, but the 
effect of mGlu2/3 receptor agonists or mGlu2 receptor 
PAMs might be limited by the down-regulation of mGlu2 
receptors, a process associated with the disorders and even 
amplified by the use of atypical antipsychotics. Thus, mGlu2 
receptors should be targeted in drug-naïve patients, 
preferentially at the first episode of psychosis, or at least in 
the early phase of the disease. One can easily predict that 
“epigenetic drugs” acting at the GRM2 gene promoter to 
enhance the expression of mGlu2 receptors may have a 
permissive effect with mGlu2 receptor agonists/PAMs in the 
treatment of SZ. Accordingly, pharmacological inhibition of 
HDACs has been shown to reverse the epigenetic down-
regulation of mGlu2 receptors caused by atypical antipsychotics 
[56]. L-acetylcarnitine enhances mGlu2 receptor expression 
via a mechanism mediated by acetylation of histones or 
transcription factors [66-68]. L-Acetylcarnitine is currently 
marketed for the treatment of neuropathic pain and shows an 
excellent profile of safety and tolerability. It will be 
interesting to examine whether L-acetylcarnitine is able to 
reverse the epigenetic programming triggered by early life 
stress by enhancing the expression of mGlu2 receptors. If so, 
a combination of mGlu2/3 receptor agonists (or mGlu2 
receptor PAMs) and L-acetylcarnitine might be proposed as 
a valuable strategy in the treatment of SZ.  
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